Abstract
Nigel S B Rawson, PhD, Canadian Health Policy Institute ABSTRACT Canada has experienced much uncertainty about the federal government’s intention to regulate lower ceiling prices for patented medicines during the past seven years. This study’s objective was
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
